Antharis engages in the discovery and development of monoclonal antibodies (mAbs) and antibody-drug conjugates as next-generation treatments for unmet medical needs.
Biological therapeutics can be more effective, specific, stable, and safer for patients relative to traditional medications; as such, they are rapidly revolutionizing multiple areas of medicine.
Antharis’ stance in creating the next generation of therapies is unique in at least three ways:
At the core of Antharis’ commitment to developing transformative medicines for patients in need is the powerful combination of innovative antibody development strategies, creative science, passionate people, and cutting-edge technologies. The use of antibodies to harness and unleash the full power of the immune system holds unparalleled potential to treat a wide array of medical conditions for which there are currently no satisfactory treatment alternatives. We trust antibody therapeutics hold tomorrow’s breakthroughs in healthcare.
